Cambridge Heart Announces Filing of Shelf Registration Statement.

BEDFORD, Mass. -- Cambridge Heart, Inc. (OTCBB:CAMH) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission, which, if and when declared effective, will permit the Company, from time to time, to offer and sell up to $20 million of equity or debt securities. The shelf registration statement will provide the Company greater flexibility to take advantage of financing opportunities, subject to market conditions and the capital requirements of the Company. As of the date of this release, the Company has no specific plans to offer the securities covered by the registration statement, and the Company is not required to offer the securities in the future.

The terms of any offering under the registration statement will be established at the time of the offering and will be described in a prospectus supplement filed at the time of the offering. Unless otherwise indicated in a prospectus supplement, the proceeds from the sale of any securities will be used for general corporate purposes including, but not limited to, sales and marketing expansion, working capital, capital expenditures, continuing research and development, acquisitions and investments.

"On our first quarter conference call we announced our intention to file a shelf registration statement" said David Chazanovitz, President and CEO of Cambridge Heart, Inc. "As we stated at that time, we do not have any immediate plans to raise additional capital, however, we believe this shelf registration statement will provide us with a greater degree of flexibility if we decide to do so in the future."

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective This press release is not an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state of jurisdiction.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of, or who are at risk of, life threatening arrhythmias that test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.